6 TECH OUTLOOKDec 2019 - Jan 2020EditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comInnovation plays an important role in drug development. Modern technology platforms, enabled with cloud, artificial intelligence (AI), and blockchain, are reducing the risks in drug development, testing, and release while ensuring there is sufficient demand for those drugs in the market. Leveraging big data, AI-enabled platforms are enabling researchers to streamline and accelerate their pre-clinical and post-clinical workflow. By analyzing billions of data points, the potential drug candidate can be examined across a myriad of data types. So the pharma and life sciences organizations can not only improve their time to market through effective compliance but also stay profitable. With efficient drugs entering the market, payers and insurance companies too can benefit from the improved patient care delivery outcomes. Amid the growing market competition and increasingly stringent compliance measures, companies in the pharma industry are under pressure to improve their bottom line. In this scenario, they need solutions that will enable them to improve their research processes and perform their business functions in more intelligent ways. In this edition of Pharma Tech Outlook, we are pleased to feature INVENesis, a Swiss biotech company that has assumed the duty to enable organizations of all sizes to excel in the arena of drug discovery. Be it a large pharma company, a startup, or a two-person operation wanting to test the potency of a compound, INVENesis has established a suitable business model to cater to their every possible request. The company enables its clients to study the effect of active ingredients on individual targets, organs, and whole organisms.In this edition, we bring to you companies that are at the forefront of delivering efficient pharma and life sciences solutions and services in the UK and Europe. The edition also features insightful articles from subject matter experts.Let us know your thoughts.Toward Efficient and Cost-Effective DrugsCopyright © 2019 ValleyMedia Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.DEC 2019 - JAN 2020, Vol 05 - Issue 21 (ISSN 2644-2787) Published by ValleyMedia Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com *Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffEditor-in-ChiefStacey SmithVisualizerAsher BlakeEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul BarberSalesBrian Thomasbrian@pharmatechoutlook.comPhone: 510.556.2402sales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:Contact Us:Phone:510.556.2402, Fax:510-894-8405Ronald DonovanTECH OUTLOOKTECH OUTLOOK
< Page 5 | Page 7 >